Literature DB >> 17250559

Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients--an analysis of USRDS data.

V R Dharnidharka1, L Y Agodoa, K C Abbott.   

Abstract

We previously showed that children are more likely to develop viral infections post-kidney transplant while adults are more likely to develop bacterial infections. In this study we determined the overall risk factors for hospitalization with either a bacterial (HBI) or a viral infection (HVI). We analyzed data from 28 924 United States Renal Data System (USRDS) Medicare primary renal transplant recipients from January 1996 to July 2000, for adjusted hazard ratio (AHR) for HBI or HVI in the first 3 years posttransplant. For HVI, significantly higher AHR was seen with (a) recipient age <18 years (AHR 1.57, 95% CI = 1.02, 2.42), (b) donor CMV positive (AHR 1.72, 95% CI = 1.34, 2.19). For HBI, significantly higher AHR was seen with (i) delayed graft function (AHR 1.28, 95% CI = 1.076, 1.518), (ii) primary renal diagnosis chronic pyelonephritis (AHR 1.71, 95% CI = 1.18, 2.49); (iii) associated pretransplant diabetes (AHR 1.80, 95% CI = 1.53, 2.12); (iv) female gender AHR 1.63, 95% CI = 1.41, 1.88). Lower AHR for HVI was seen in CMV-positive recipients and for HBI with more recent year of transplant. Other covariates did not impact significantly in either HVI or HBI.

Entities:  

Mesh:

Year:  2007        PMID: 17250559     DOI: 10.1111/j.1600-6143.2006.01674.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  21 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Secular Trends in Infection-Related Mortality after Kidney Transplantation.

Authors:  Susanna Kinnunen; Pauli Karhapää; Auni Juutilainen; Patrik Finne; Ilkka Helanterä
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-05       Impact factor: 8.237

Review 3.  Calcineurin inhibitors in HLA-identical living related donor kidney transplantation.

Authors:  Priya S Verghese; Ty B Dunn; Srinath Chinnakotla; Kristin J Gillingham; Arthur J Matas; Michael S Mauer
Journal:  Nephrol Dial Transplant       Date:  2014-01       Impact factor: 5.992

4.  Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation.

Authors:  Meghan H Pearl; Qiuheng Zhang; Miguel Fernando Palma Diaz; Jonathan Grotts; Maura Rossetti; David Elashoff; David W Gjertson; Patricia Weng; Elaine F Reed; Eileen Tsai Chambers
Journal:  Kidney Int       Date:  2017-09-18       Impact factor: 10.612

Review 5.  Gender Mainstreaming and Transplant Surgery.

Authors:  Eva Maria Teegen; Isabell Krebs; Corinna Langelotz; Johann Pratschke; Beate Rau
Journal:  Visc Med       Date:  2016-07-29

Review 6.  Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.

Authors:  Britta Höcker; Burkhard Tönshoff
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 7.  Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.

Authors:  Roberto Marcén
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

8.  Clinical and economic consequences of first-year urinary tract infections, sepsis, and pneumonia in contemporary kidney transplantation practice.

Authors:  Abhijit S Naik; Vikas R Dharnidharka; Mark A Schnitzler; Daniel C Brennan; Dorry L Segev; David Axelrod; Huiling Xiao; Lauren Kucirka; Jiajing Chen; Krista L Lentine
Journal:  Transpl Int       Date:  2015-12-09       Impact factor: 3.782

Review 9.  A Rationale for Age-Adapted Immunosuppression in Organ Transplantation.

Authors:  Felix Krenzien; Abdallah ElKhal; Markus Quante; Hector Rodriguez Cetina Biefer; Uehara Hirofumi; Steven Gabardi; Stefan G Tullius
Journal:  Transplantation       Date:  2015-11       Impact factor: 4.939

10.  Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent.

Authors:  Priya S Verghese; Mark R Schleiss
Journal:  Drugs Future       Date:  2013-05       Impact factor: 0.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.